![\"A](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/a-blood-based-genetic.jpg\" "\\"Transcriptomic")
<\/p>\n <\/p>\n
Transcriptomic profiling of lymphoid cell subpopulations. Credit: Brain (2025). DOI: 10.1093\/brain\/awaf066<\/p>\n
Parkinson’s disease is best known for its effects on the central nervous system. In addition, recent scientific advances generally emphasize the role of the immune system in the presence and development of the disease.<\/p>\n
In a study published<\/a> in Brain, researchers led by Universit\u00e9 de Montr\u00e9al associate professor of neuroscience Martine T\u00e9treault show that some cell types in the immune system are activated more in patients who have Parkinson’s.<\/p>\n “Thanks to a new technology called single-cell RNA-seq, we can differentiate the cellular subtypes and observe gene expression<\/a> at the cellular level for each cell,” explained T\u00e9treault, a research scientist at the CRCHUM, Universit\u00e9 de Montr\u00e9al’s affiliated hospital research center.<\/p>\n “We found that in Parkinson’s patients, immune cells<\/a> in the blood were activated and overexpressed genes associated with stress responses,” she said. “Together, these biomarkers<\/a> form the signature of the disease.”<\/p>\n T\u00e9treault conducted the study with three co-first authors: Ga\u00ebl Moquin-Beaubry, a former postdoctoral fellow in her lab, and current Ph.D. candidates Lovatiana Andriamboavonjy and S\u00e9bastien Audet.<\/p>\n Noting the current lack of clinical biomarkers needed to diagnose Parkinson’s, the researchers believe that knowing the disease’s unique signature could help clinical teams diagnose it early on, from a blood sample<\/a>.<\/p>\n The set of biomarkers could also make it easier to distinguish the disease from other similar rare diseases, especially Parkinsonian syndromes such as progressive supranuclear palsy<\/a> (PSP), and multiple system atrophy (MSA).<\/p>\n 14 patients tested<\/p>\n In their study, the research team analyzed blood samples from 14 CHUM patients with a confirmed diagnosis of Parkinson’s and six patients presenting with Parkinsonian syndromes, comparing them with a control group of 10 healthy people.<\/p>\n “In our study, the gene signature of the disease allowed us to distinguish between patients with Parkinson’s disease and those with Parkinsonian syndromes,” said T\u00e9treault. “These biomarkers could improve diagnostic reliability or facilitate participant selection for clinical trials<\/a> testing the efficacy of a drug for this disease.”<\/p>\n Her research team is now making available to other scientists a complete atlas of immune system cellular subtypes found in healthy individuals and people with Parkinson’s.<\/p>\n In 2024, approximately 110,000 Canadians were living with Parkinson’s disease. By 2034, that number is expected to grow to around 150,000.<\/p>\n More information:<\/strong> \t\t\t\t\t\t\t\t\t\t\t\t\tJournal information:<\/strong> \t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/a> <\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\tProvided by \n Citation<\/strong>: \n This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
\n Gael Moquin-Beaudry et al, Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing, Brain (2025). DOI: 10.1093\/brain\/awaf066<\/a><\/p>\n
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tBrain<\/a>
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/p>\n
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tUniversity of Montreal Hospital Research Centre (CRCHUM)<\/p>\n
\n Diagnosing Parkinson’s using a blood-based genetic signature (2025, May 28)
\n retrieved 28 May 2025
\n from https:\/\/medicalxpress.com\/news\/2025-05-parkinson-blood-based-genetic-signature.html\n <\/p>\n
\n part may be reproduced without the written permission. The content is provided for information purposes only.\n <\/p>\n","protected":false},"excerpt":{"rendered":"Transcriptomic profiling of lymphoid cell subpopulations. Credit: Brain (2025). DOI: 10.1093\/brain\/awaf066 Parkinson’s disease is best known for its…\n","protected":false},"author":2,"featured_media":139919,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[267,1555,1554,1556,1553,1552,1557,70,16,15],"class_list":{"0":"post-139918","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-health-research","10":"tag-health-research-news","11":"tag-health-science","12":"tag-medicine-research","13":"tag-medicine-research-news","14":"tag-medicine-science","15":"tag-science","16":"tag-uk","17":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114588007067718114","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/139918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=139918"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/139918\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/139919"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=139918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=139918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=139918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}